about
Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1.Phase II/III randomized trial of TCH346 in patients with ALSDifferentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-upAnalysis of novel NEFL mRNA targeting microRNAs in amyotrophic lateral sclerosisCharacterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis.Neurofilament metabolism in sporadic amyotrophic lateral sclerosis.Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults.The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases.Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQGenetic modifiers in carriers of repeat expansions in the C9ORF72 gene.Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the AmAtaxin-2 repeat-length variation and neurodegenerationThe basic aspects of therapeutics in amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis: a review of current concepts.Prognosis of amyotrophic lateral sclerosis with respiratory onset.Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum?Innate immunity in amyotrophic lateral sclerosis.Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotypePathological tau deposition in Motor Neurone Disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathyTransient middle cerebral artery occlusion induces microglial priming in the lumbar spinal cord: a novel model of neuroinflammationPost-transcriptional control of neurofilaments in development and disease.C9ORF72 repeat expansions in cases with previously identified pathogenic mutations.The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis.Threonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies.The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS).TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia.The frontotemporal syndromes of ALS. Clinicopathological correlates.Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology.Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis.Genetic and epigenetic studies of amyotrophic lateral sclerosis.RNA metabolism in ALS: when normal processes become pathological.RNA-binding proteins as molecular links between cancer and neurodegeneration.Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.Tau protein aggregation in the frontal and entorhinal cortices as a function of aging.Microtubule-associated tau protein positive neuronal and glial inclusions in ALS.Nitric oxide synthase expression in cervical spinal cord in sporadic amyotrophic lateral sclerosis.Frontotemporal Dysfunction and Dementia in Amyotrophic Lateral Sclerosis.The Ontario Neurodegenerative Disease Research Initiative (ONDRI).Motor unit estimates in the biceps-brachialis in amyotrophic lateral sclerosis.Methods for estimating numbers of motor units in biceps-brachialis muscles and losses of motor units with aging.
P50
Q27301265-74E18582-0584-4708-8623-14829A2627C7Q28241484-BEAD5B95-0AAA-4BF2-9EA4-EEDBC6826846Q28287954-255C6692-7402-4945-A67E-95DC79FD296CQ28538722-D70AAE5B-4EEB-4E0D-B7C3-773785800157Q30941385-267C3A66-B63E-4832-8891-368FF64559BEQ33762430-78F94E6D-572D-45B4-95A7-06F2AD0CAD0BQ34039333-507CDC44-A940-46C7-BE94-C593C601B2C6Q34159126-0699DC40-CF4A-42D2-A8F3-4814D5C9039EQ34281634-EF622FE3-AF21-43E5-BEE9-F740356C99E8Q34308707-E35811D0-4AA3-4C63-9DD7-3FD44FB8A324Q35007618-CE3727CA-2059-4303-81F7-E81B74212BB7Q35119694-D2CA4B77-66D5-4C7E-BC0F-1C01B662415BQ35143367-4CAD8B79-D048-4371-BBC2-B66EEAFACA73Q35226371-4766D46B-F9CC-48EC-BDCE-89644B4B5EFDQ36143806-62F90520-3F6F-4F85-9E69-3ADB563F462FQ36203594-319463A3-BF22-41DA-9F1F-699EB611F668Q36453605-6ACFE0CA-FCFE-49CD-93D8-5A4BD616A695Q36742669-13225EE0-8812-4BA8-9C1B-A16F46F86BEEQ36758306-9AACFE3C-A830-45E4-8FE5-7192BD8CF591Q36775607-3900FE2B-1BC8-42E1-B719-1B4DDB8BC157Q36788691-D7D1DBE1-3EFC-491E-8666-CD75AE189B07Q37251674-9C255731-DB71-456E-BC9C-652E68F08C5AQ37254394-A1AC6D5E-837E-490D-97A4-847177673CE6Q37579193-4BAC7FEE-E66A-4A89-A74D-316A4DEC1A58Q37617743-AA4E5351-92CB-427F-B7FD-93DD7917984FQ37621660-74A5CF72-1CF7-4348-B87B-14FCEC75A36EQ37910033-D4344686-50C4-4D21-B333-6B4212A6FB57Q37959310-156B6A7C-5B6E-4B97-8428-6D652D827089Q37976113-63918430-3241-4A7E-9BB8-D97E8734C035Q38107218-ED4084C4-E34D-4FD0-898D-B097615C8903Q38189807-76D00DDB-C992-4387-9315-8775791C3692Q38251313-30CB779D-6722-4717-B332-5C02FAF46605Q38312121-A66BFD06-B47C-40F5-AEA1-AC30D1B3C0CAQ38441372-15B375D6-6053-417C-A645-0BE3059FC49BQ38449470-97E7827D-F5C8-4F30-A8E1-E416AD455AC8Q38469512-DCD46DE2-EA56-422B-BA33-DB338A851129Q38619902-59CED9D5-9DFC-4341-B76A-14715C8C2196Q39077109-4BA13324-11C2-437F-B376-D952D1E3DB3EQ39104513-83E937DE-279A-4DC5-915A-A32BC4D2AEE8Q39104519-31781AE5-94C3-4441-88E4-5D1B0677BFED
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0003-1988-6262
@en
name
Michael J Strong
@ast
Michael J Strong
@en
Michael J Strong
@es
Michael J Strong
@nl
type
label
Michael J Strong
@ast
Michael J Strong
@en
Michael J Strong
@es
Michael J Strong
@nl
prefLabel
Michael J Strong
@ast
Michael J Strong
@en
Michael J Strong
@es
Michael J Strong
@nl
P214
P244
P106
P1153
7101816660
P214
P244
n2003127629
P31
P496
0000-0003-1988-6262
P734
P735
P7859
lccn-n2003127629